Wegovy supply problems that began in 2021 grew into a shortage FDA resolved in 2025
The early Wegovy supply disruption led to a shortage that lasted until February 2025 and opened the door to compounded semaglutide, which now faces wind-down deadlines.
Supply problems that started within months of Wegovy's June 2021 approval grew into the shortage that the Food and Drug Administration declared resolved on February 21, 2025 [1]. The order closing out that shortage also set deadlines for compounded semaglutide, which had grown into a substantial alternative while the branded pens were scarce [1].
The FDA order does not describe the manufacturing problem at the contract filling partner that first constrained supply in late 2021. It focuses on how the shortage ended, not how it began [1].
What the order does document is the timeline. Wegovy, approved in June 2021 under NDA 215256, was added to FDA's drug shortage list on March 31, 2022 [1]. Ozempic, approved in December 2017 under NDA 209637, was added on August 23, 2022 [1]. FDA notes that Ozempic and Wegovy are the only approved semaglutide injection products, and that Rybelsus, the oral semaglutide tablet, was not in shortage [1].
FDA said it based its decision on Novo Nordisk data showing the company's supply was "currently meeting or exceeding demand," with reserves held in finished-product inventory plus "significant units of semi-finished product" [1].
The agency also acknowledged that national supply and individual experience can differ. FDA said it had received reports that some patients and pharmacists could not get the drugs, and that "a substantial amount of semaglutide compounding" was occurring [1]. It said such intermittent problems were most likely explained by the part of the supply chain between Novo Nordisk and its customers, including wholesale distributors and pharmacies, rather than by a continuing national shortage [1].
Public updates from late 2024 show the shift. On October 2, 2024, FDA still listed semaglutide injection products as in shortage, but noted Novo Nordisk had "reported all but one of the presentations are available" [1]. By December 19, 2024, FDA said the company had "reported all presentations are available" and that the agency was actively monitoring availability [1].
Why it matters for patients
The order creates two deadlines for compounded semaglutide. FDA said it does not intend to take action against state-licensed pharmacists or physicians compounding under section 503A for violations that depend on the shortage listing for 60 days, until April 22, 2025 [1]. For outsourcing facilities under section 503B, the window is 90 days, until May 22, 2025 [1]. The order does not describe what happens after those dates beyond the end of that discretion [1].
FDA said some patients now receiving compounded semaglutide can be expected to seek approved products once compounding is curtailed, and it judged that Novo Nordisk's supply could absorb that demand [1].
FDA also said a resolved national shortage does not guarantee a smooth experience at a local pharmacy, and that patients and prescribers may still see intermittent shortages as products move through the supply chain [1]. Whether insurers will cover a switch from a compounded product to an approved one, and at what cost, is not addressed in the order [1].
What happens next
- April 22, 2025: the 60-day enforcement window for state-licensed pharmacists and physicians compounding under section 503A ends [1].
- May 22, 2025: the 90-day window for outsourcing facilities under section 503B ends [1].
- FDA said it will continue to monitor supply and demand and consider whether semaglutide injection products should go back on the shortage list [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.